Zhuochen Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhuochen Yu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Lili Zhou
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China
2 shared publications - Wenjing He
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China
2 shared publications - Debiao Xiang
Department of Pharmacy, The Third Hospital of Changsha, Changsha, 410035, People’s Republic of China
1 shared publication Haiyu Hu
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China
1 shared publication- Xinhua Xia
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China
1 shared publication - Yating Shang
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-50
Emerging Nanoplatforms are Effective Against Tumor Hypoxia
Hypoxia is a characteristic feature of the solid tumor microenvironment and serves as a pivotal factor in tumor progression, metastasis, and therapeutic resistance. It has long been recognized as a significant barrier to advancing cancer therapy. Although traditional oxygen supplementation strategies can partially enhance local oxygen levels, their effectiveness is limited by the spatiotemporal heterogeneity of tumor tissues, low delivery efficiency, and biosafety concerns, making them inadequate for the precise oxygen regulation required by the complex tumor microenvironment. In recent years, nanotechnology-based platforms designed to alleviate hypoxia have emerged as innovative approaches for remodeling the tumor microenvironment and enhancing multimodal synergistic therapies. These platforms operate through three primary strategies: exogenous oxygen delivery, endogenous oxygen generation, and metabolic oxygen conservation. This review systematically elucidates the underlying mechanisms of tumor hypoxia, summarizes the design principles and recent advancements of related nanomedicines, and discusses the potential and challenges of these platforms in multimodal combination therapies. The study aims to furnish a comprehensive reference for the design of hypoxia-alleviating nanoplatforms and the optimization of synergistic therapeutic strategies, with the objective of providing novel insights and prospects for the development of nanomaterials in this domain.
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-50
Open AccessEmerging Nanoplatforms are Effective Against Tumor Hypoxia
Hypoxia is a characteristic feature of the solid tumor microenvironment and serves as a pivotal factor in tumor progression, metastasis, and therapeutic resistance. It has long been recognized as a significant barrier to advancing cancer therapy. Although traditional oxygen supplementation strategies can partially enhance local oxygen levels, their effectiveness is limited by the spatiotemporal heterogeneity of tumor tissues, low delivery efficiency, and biosafety concerns, making them inadequate for the precise oxygen regulation required by the complex tumor microenvironment. In recent years, nanotechnology-based platforms designed to alleviate hypoxia have emerged as innovative approaches for remodeling the tumor microenvironment and enhancing multimodal synergistic therapies. These platforms operate through three primary strategies: exogenous oxygen delivery, endogenous oxygen generation, and metabolic oxygen conservation. This review systematically elucidates the underlying mechanisms of tumor hypoxia, summarizes the design principles and recent advancements of related nanomedicines, and discusses the potential and challenges of these platforms in multimodal combination therapies. The study aims to furnish a comprehensive reference for the design of hypoxia-alleviating nanoplatforms and the optimization of synergistic therapeutic strategies, with the objective of providing novel insights and prospects for the development of nanomaterials in this domain.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-40
Key Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics
The intricate pathological features of the tumor microenvironment (TME) collectively contribute to therapeutic resistance, thereby substantially constraining the antitumor efficacy of conventional treatments. Zeolitic imidazolate framework-8 (ZIF-8), a pH-responsive metal-organic framework material, serves not only as an efficient drug delivery system but also actively participates in TME remodeling through the release of Zn2+ upon its degradation. This dual function as both a “carrier” and an “effector” offers a synergistic mechanism to mitigate therapeutic resistance. The article reviews recent research on ZIF-8, focusing on its role in targeted drug delivery and its transformation from a passive carrier to an active modulator of cellular environments. It examines how ZIF-8’s synthetic pathways and surface modifications aid in delivering various drugs and analyzes the molecular mechanisms by which released Zn2+ triggers stress responses and immune reactions. The article also discusses ZIF-8’s integration into theranostic platforms, its use in combination therapies, and the clinical translation challenges, including biosafety, reproducibility, and scalable production. This review aims to systematically synthesize existing knowledge across the aforementioned fields to establish a theoretical foundation for the design of next-generation ZIF-8 nanotheranostic systems and facilitate their progression toward clinical translation. The infographic illustrates the TME-responsive ZIF-8 nanoplatform for cancer therapy. It begins with the synthesis process, showing Zn superscript 2 plus and 2-Methylimidazole forming ZIF-8, which is then functionalized with drugs for EPR effect and ligand targeting. The acidic TME-responsive degradation leads to drug and Zn superscript 2 plus release. Combination therapies include chemotherapy, radiotherapy and immunotherapy. The dual ’Carrier-Effecter’ mechanism involves pH-responsive drug and Zn superscript 2 plus release targeting cancerous tumors, leading to DAMPs release, ICD, ROS production and activation of caspase and GSDMD. This process stimulates maturation and activation of DCs and mDCs, enhancing CD8 superscript plus T cells and CD4 superscript plus T cells. Theranostics involve imaging (MRI, PET) and image-guided therapy. The outlook emphasizes rational design, scalable synthesis, multifunctionality, clinical translation and personalized precision medicine.TME-responsive ZIF-8 nanoplatform: cancer therapy with theranostics and dual strategies.
- 1 May 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-40
Open AccessKey Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics
The intricate pathological features of the tumor microenvironment (TME) collectively contribute to therapeutic resistance, thereby substantially constraining the antitumor efficacy of conventional treatments. Zeolitic imidazolate framework-8 (ZIF-8), a pH-responsive metal-organic framework material, serves not only as an efficient drug delivery system but also actively participates in TME remodeling through the release of Zn2+ upon its degradation. This dual function as both a “carrier” and an “effector” offers a synergistic mechanism to mitigate therapeutic resistance. The article reviews recent research on ZIF-8, focusing on its role in targeted drug delivery and its transformation from a passive carrier to an active modulator of cellular environments. It examines how ZIF-8’s synthetic pathways and surface modifications aid in delivering various drugs and analyzes the molecular mechanisms by which released Zn2+ triggers stress responses and immune reactions. The article also discusses ZIF-8’s integration into theranostic platforms, its use in combination therapies, and the clinical translation challenges, including biosafety, reproducibility, and scalable production. This review aims to systematically synthesize existing knowledge across the aforementioned fields to establish a theoretical foundation for the design of next-generation ZIF-8 nanotheranostic systems and facilitate their progression toward clinical translation. The infographic illustrates the TME-responsive ZIF-8 nanoplatform for cancer therapy. It begins with the synthesis process, showing Zn superscript 2 plus and 2-Methylimidazole forming ZIF-8, which is then functionalized with drugs for EPR effect and ligand targeting. The acidic TME-responsive degradation leads to drug and Zn superscript 2 plus release. Combination therapies include chemotherapy, radiotherapy and immunotherapy. The dual ’Carrier-Effecter’ mechanism involves pH-responsive drug and Zn superscript 2 plus release targeting cancerous tumors, leading to DAMPs release, ICD, ROS production and activation of caspase and GSDMD. This process stimulates maturation and activation of DCs and mDCs, enhancing CD8 superscript plus T cells and CD4 superscript plus T cells. Theranostics involve imaging (MRI, PET) and image-guided therapy. The outlook emphasizes rational design, scalable synthesis, multifunctionality, clinical translation and personalized precision medicine.TME-responsive ZIF-8 nanoplatform: cancer therapy with theranostics and dual strategies.